As 2018 draws to a close, Ardelyx shares appear to offer compelling value. The company's market value is trading below the value of the cash it holds on its balance sheet, and its pipeline looks promising. Tenapanor is a highly differentiated drug which could be approved for IBS-C or ESRD (or both).
Happy New Year! Here Is A 2019 Stock Idea For Your Investment Consideration
Forbes - 31 Dec 2018 19:16
As 2018 draws to a close, Ardelyx shares appear to offer compelling value. The company's market value is trading below the value of the cash it holds on its balance sheet, and its pipeline looks promising. Tenapanor is a highly differentiated drug which could be approved for IBS-C or ESRD (or both).
Share this Article
Recommended